Insights › Medicine & pharma › November 13, 2026
Medicine & pharma · Official intelligence

EMA recommends approval for Zybrivo (sintilimab) for NSCLC

European Union EMA (New human medicines) Published:

On 12 November 2026, the EMA's CHMP adopted a positive opinion recommending marketing authorization for Zybrivo (sintilimab). The applicant Fortvita seeks approval for this medicine to treat non-squamous non-small cell lung cancer in adults. This expands immunotherapy options for this specific cancer subtype.

Original source
Read the source — ema.europa.eu ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.